519032-07-6

Basic information

• Product Name: 2-BENZYL-5,6-DIHYDROXY-PYRIMIDINE-4-CARBOXYLIC ACID METHYL ESTER
• Synonyms: 2-BENZYL-5,6-DIHYDROXY-PYRIMIDINE-4-CARBOXYLIC ACID METHYL ESTER
• CAS NO: 519032-07-6
• Molecular Formula: C₁₃H₁₂N₂O₄
• Molecular Weight: 260.24538
• Mol File: 519032-07-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-BENZYL-5,6-DIHYDROXY-PYRIMIDINE-4-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BENZYL-5,6-DIHYDROXY-PYRIMIDINE-4-CARBOXYLIC ACID METHYL ESTER(519032-07-6)
• EPA Substance Registry System: 2-BENZYL-5,6-DIHYDROXY-PYRIMIDINE-4-CARBOXYLIC ACID METHYL ESTER(519032-07-6)

Safety Data

• Hazardous Substances Data: 519032-07-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2-BENZYL-5,6-DIHYDROXY-PYRIMIDINE-4-CARBOXYLIC ACID METHYL ESTER is used as a building block for the synthesis of various compounds in pharmaceutical research, due to its potential to contribute to the development of new drugs with unique therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, 2-BENZYL-5,6-DIHYDROXY-PYRIMIDINE-4-CARBOXYLIC ACID METHYL ESTER is used as a key intermediate, enabling the construction of complex organic molecules for a wide range of applications.
Used in Agriculture:
Although further research is needed, 2-BENZYL-5,6-DIHYDROXY-PYRIMIDINE-4-CARBOXYLIC ACID METHYL ESTER may be used in agriculture for the development of new agrochemicals or as a component in the synthesis of bioactive compounds with potential applications in crop protection or enhancement.
Used in Materials Science:
Similarly, in materials science, 2-BENZYL-5,6-DIHYDROXY-PYRIMIDINE-4-CARBOXYLIC ACID METHYL ESTER may have potential applications, possibly contributing to the development of new materials with unique properties, pending further exploration of its characteristics and capabilities.

Upstream product

• 878650-03-4 (E)-2-[(2-Phenyl-acetimidoyl)-aminooxy]-but-2-enedioic acid dimethyl ester 
• 878650-03-4 2-[(2-phenyl-acetimidoyl)-aminooxy]-but-2-enedioic acid dimethyl ester 
• 19227-11-3 N'-hydroxy-2-phenylethanimidamide 
• 762-42-5 dimethyl acetylenedicarboxylate 
• 19227-11-3 (Z)-N'-hydroxy-2-phenylacetimidamide 
• 19227-11-3 N-hydroxy-2-phenylethanimidamide 
• 140-29-4 phenylacetonitrile 

Downstream Products

• 519031-80-2 methyl 5,6-bis(benzoyloxy)-2-benzylpyrimidine-4-carboxylate 
• 1027839-33-3 5-benzoyloxy-2-(dimethylamino-phenyl-methyl)-6-hydroxy-pyrimidine-4-carboxylic acid methyl ester 
• 1027272-12-3 5-benzoyloxy-6-hydroxy-2-(morpholin-4-yl-phenyl-methyl)-pyrimidine-4-carboxylic acid methyl ester 
• 519031-81-3 methyl 5,6-bis(benzoyloxy)-2-[bromo(phenyl)methyl]pyrimidine-4-carboxylate 
• 1026055-06-0 5-benzoyloxy-6-hydroxy-2-(phenyl-piperidin-1-yl-methyl)-pyrimidine-4-carboxylic acid methyl ester 
• 1194473-20-5 4,5-dihydroxy-2-benzylpyrimidine 

Relevant articles and documents

Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-D-ribose 2′-Oxidase

Magnesium plays an important role in infection with Mycobacterium tuberculosis (Mtb) as a signal of the extracellular environment, as a cofactor for many enzymes, and as a structural element in important macromolecules. Raltegravir, an antiretroviral drug

NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY

The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particuarl embodiments, the compositions target DXR. In specific embodiments, the compositions are electron-deficient heterocyclic rings.

Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase

1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) in the non-mevalonate pathway found in most bacteria is a validated anti-infective drug target. Fosmidomycin, a potent DXR inhibitor, is active against Gram-negative bacteria. A coordination chemistry and structure based approach was used to discover a novel, lipophilic DXR inhibitor with an IC50 of 1.4 μM. It exhibited a broad spectrum of activity against Gram-negative and -positive bacteria with minimal inhibition concentrations of 20-100 μM (or 3.7-19 μg/mL).

RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: Design, biochemical activity, and structural information

Pyrimidinol carboxylic acids were designed as inhibitors of HIV-1 RNase H function. These molecules can coordinate to two divalent metal ions in the RNase H active site. Inhibition of enzymatic activity was measured in a biochemical assay, but no antivira

Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors

Human immunodeficiency virus type-1 (HIV-1) integrase, one of the three constitutive viral enzymes required for replication, is a rational target for chemotherapeutic intervention in the treatment of AIDS that has also recently been confirmed in the clinical setting. We report here on the design and synthesis of N-benzyl-5,6-dihydroxypyrimidine-4-carboxamides as a class of agents which exhibits potent inhibition of the HIV-integrase-catalyzed strand transfer process. In the current study, structural modifications on these molecules were made in order to examine effects on HIV-integrase inhibitory potencies. One of the most interesting compounds for this series is 2-[1-(dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 38, with a CIC95 of 78 nM in the cell-based assay in the presence of serum proteins. The compound has favorable pharmacokinetic properties in preclinical species (rats, dogs, and monkeys) and shows no liabilities in several counterscreening assays, highlighting its potential as a clinically useful antiviral agent.

2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: Discovery, SAR, modeling, and mutagenesis

Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand. The polymerase of HCV is responsible for the replication of viral RNA. We recently disclosed dihydroxypyrimidine carboxylates 2 as novel, reversible inhibitors of the HCV NS5B polymerase. This series was further developed into 5,6-dihydroxy-2-(2- thienyl)pyrimidine-4-carboxylic acids such as 34 (EC50 9.3 μM), which now show activity in the cell-based HCV replication assay. The structure-activity relationship of these inhibitors is discussed in the context of their physicochemical properties and of the polymerase crystal structure. We also report the results of mutagenesis experiments which support the proposed binding model, which involves pyrophosphate-like chelation of the active site Mg ions.

4,5-Dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species

The dihydroxypyrimidine carboxamide 4a was discovered as a potent and selective HIV integrase strand transfer inhibitor. The optimization of physicochemical properties, pharmacokinetic profiles, and potency led to the identification of 13 in the dihydroxypyrimidine series and 18 in the N-methylpyrimidinone series having low nanomolar activity in the cellular HIV spread assay in the presence of 50% normal human serum and very good pharmacokinetics in preclinical species.